GlassScriptPhysician profile
Michael Todd Faulkner
NPI 1467166983
$1,693.99
in general payments reported to CMS, 2019-2025
26 companies · $1,446 in 2025
The $1,446 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $248 · 2025: $1,446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,693.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $354.55 | 2024-2025 | |
| Novo Nordisk INC | $176.14 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $158.50 | 2024-2025 | |
| Glaxosmithkline, LLC. | $153.41 | 2025 | Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $129.21 | 2024-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $86.65 | 2024-2025 | Jardiance, Mounjaro, Zepbound |
| Lundbeck LLC | $60.16 | 2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.17 | 2025 | Caplyta |
| Amgen INC. | $54.79 | 2025 | Evenity |
| Teva Pharmaceuticals USA, INC. | $53.35 | 2025 | Austedo Xr, Ajovy |
| Ani Pharmaceuticals, INC. | $47.53 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $45.48 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.30 | 2024-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.53 | 2024-2025 | Xifaxan |
| Corcept Therapeutics | $28.17 | 2025 | Korlym |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $24.29 | 2025 | Voquezna |
| Abbott Laboratories | $23.84 | 2025 | Freestyle Libre 3 |
| Dexcom, INC. | $23.33 | 2025 | Dexcom G6 Transmitter |
| Insulet Corporation | $21.43 | 2025 | Omnipod |
| Xeris Pharmaceuticals, INC. | $19.58 | 2025 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $19.06 | 2025 | Inspire |
| Astellas Pharma US INC | $16.72 | 2024 | Veozah |
| Exact Sciences Corporation | $15.97 | 2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $15.86 | 2025 | Trintellix |
| Merck Sharp & Dohme LLC | $15.63 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Viatris Specialty LLC | $15.34 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Faulkner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.